French biotech Deinove has acquired, through a contribution-in-kind transaction, the entire capital of Austrian biotech Biovertis AG and its wholly owned German subsidiary Morphochem AG. The deal also provides Deinove with MCB3837, an IV compound developed by Morphochem to treat severe gastrointestinal infections cause by Clostridium difficile which is currently ipoised to enter Phase II.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?